|Table of Contents|

Web of science-based immune checkpoint inhibitors research status and hot spot analysis of its application in the treatment of lung cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2022 05
Page:
891-895
Research Field:
Publishing date:

Info

Title:
Web of science-based immune checkpoint inhibitors research status and hot spot analysis of its application in the treatment of lung cancer
Author(s):
ZHANG Yu1; XU Yan2; CUI Qian1; WANG Sue2; JI Shuo2; ZOU Haiou1; PAN Ruili2
1.School of Nursing,Peking Union Medical College,Beijing 100144,China；2.Peking Union Medical College Hospital,Beijing 100730,China.
Keywords:
lung cancer; ICIs; cluster analysis; bibliometrics
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2022.05.028
Abstract:
Objective:To conduct a quantitative analysis on the relevant literatures about the application of immune checkpoint inhibitors(ICIs)in the treatment of lung cancer from the self-built database of Web of Science,and to discuss the hot spots and research trends in this field.Methods:Retrieved the literature collection of Web of Science,and analyzed the data with Excel and VosViewer.Results:A total of 4 698 literatures were retrieved,and 1 973 effective literatures were obtained after screening.The analysis results showed that the number of foreign literatures of ICIs application in the treatment of lung cancer was increasing year by year.There were many kinds of periodicals included,up to 334.The foreign literature in the field of ICIS treatment of lung cancer mainly covers four topics.Conclusion:In recent years,much attention has been paid to research on lung cancer immunotherapy,foreign researches mainly concentrated in the prognostic biomarkers in patients with lung cancer treated with ICIs,the efficacy of combination therapy,the immune-related adverse events and the safety and efficacy in the elderly patients treated with ICIs.In the future,we should strengthen the cooperation between countries and make the toxicity of ICIs,the prognostic factors of ICIS in the treatment of lung cancer,combined chemotherapy and other related research contents become the direction of future research efforts in this field in China and even all around the world.

References:

[1] SIEGEL RL,MILLER KD,JEMAL A.Cancer statistics,2020［J］.CA:A Cancer Journal for Clinicians,2020,70(1):7-30.
[2] WOOD DE,KAZEROONI EA,BAUM SL,et al.Lung cancer screening,version 3.2018,nccn clinical practice guidelines in oncology［J］.J Natl Compr Canc Netw,2018,16(4):412-441.
[3] JAIN P,JAIN C,VELCHETI V.Role of immune-checkpoint inhibitors in lung cancer［J］.Ther Adv Respir Dis,2018,12:1825482181.
[4] WANG S,HAO J,WANG H,et al.Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer［J］.Oncoimmunology,2018,7(8):e1457600.
[5] ESPOSITO G,PALUMBO G,CARILLIO G,et al.Immunotherapy in small cell lung cancer［J］.Cancers(Basel),2020,12(9):846-847.
[6] VADDEPALLY RK,KHAREL P,PANDEY R,et al.Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence［J］.Cancers(Basel),2020,12(3):738.
[7] BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2018,68(6):394-424.
[8] LI Y,LYU M,LIU J,et al.The top 100 most frequently cited publications concerning anti-PD-1/PD-L1［J］.Lung Cancer,2021,13:1383-1393.
[9] ALLEGRANZI B,BAGHERI NS,COMBESCURE C,et al.Burden of endemic health-care-associated infection in developing countries:systematic review and meta-analysis［J］.Lancet,2011,377(9761):228-241.
[10] STUPP R,MASON W P,VAN DEN BENT MJ,et al.Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma［J］.N Engl J Med,2005,352(10):987-996.
[11] PRADHAN M,CHOCRY M,GIBBONS DL,et al.Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer［J］.Translational Lung Cancer Research,2021,10(1):590-606.
[12] DEMPKE WCM,FENCHEL K,DALE SP.Programmed cell death ligand-1(PD-L1)as a biomarker for non-small cell lung cancer(NSCLC)treatment-are we barking up the wrong tree［J］.Translational Lung Cancer Research,2018,7(S3):S275-S279.
[13] HEEKE S,HOFMAN P.Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients:getting ready for prime-time or not［J］.Translational Lung Cancer Research,2018,7(5):631-638.
[14] WANG W,GREEN M,CHOI JE,et al.CD8(+)T cells regulate tumour ferroptosis during cancer immunotherapy［J］.Nature,2019,569(7755):270-274.
[15] DAFNI U,TSOURTI Z,VERVITA K,et al.Immune checkpoint inhibitors,alone or in combination with chemotherapy,as first-line treatment for advanced non-small cell lung cancer.A systematic review and network meta-analysis［J］.Lung Cancer,2019,134:127-140.
[16] SCHOUTEN RD,EGBERINK L,MULLER M,et al.Nivolumab in pre-treated advanced non-small cell lung cancer:long term follow up data from the Dutch expanded access program and routine clinical care［J］.Translational Lung Cancer Research,2020,9(5):1736-1748.
[17] HELLMANN MD,PAZ-ARES L,BERNABE CR,et al.Nivolumab plusipilimumab in advanced non-small-cell lung cancer［J］.N Engl J Med,2019,381(21):2020-2031.
[18] HU Y,ZHANG Q,LI H,et al.Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer:a meta-analysis［J］.Translational Lung Cancer Research,2017,6(S1):S8-S20.
[19] HARADA K,OGASAWARA M,SHIDO A,et al.Pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma:A case report and review of the literature［J］.Thoracic Cancer,2020,11(5):1350-1353.
[20] SUGANO T,SEIKE M,SAITO Y,et al.Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer［J］.Thoracic Cancer,2020,11(4):1052-1060.
[21] KOMIYA K,NAKAMURA T,ABE T,et al.Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer［J］.Thoracic Cancer,2019,10(9):1798-1804.
[22] KUON J,HOMMERTGEN A,KRISAM J,et al.Durvalumab in frail and elderly patients with stage four non-small cell lung cancer:Study protocol of the randomized phase Ⅱ DURATION trial［J］.Trials,2020,21(1):352.
[23] CASALUCE F,SGAMBATO A,MAIONE P,et al.Lung cancer,elderly and immune checkpoint inhibitors［J］.J Thorac Dis,2018,10(13):S1474-S1481.

Memo

Memo:
National Natural Science Foundation of China(No.82003309）;国家自然科学青年科学基金项目(编号：82003309)；北京协和医院护理科研课题（编号：XHHLKY201902）
Last Update: 2022-01-27